Microcap Ledger BioNexus Gene Lab Corp $BGLC
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Services-Medical Laboratories
- Headquarters
- Kuala Lumpur
- Fiscal year end
- December 31
- Shares outstanding
- 2,933,442 [10-Q 2026-08-14]
What the company doesAI summary of filing
BioNexus Gene Lab Corp. operates two business divisions through wholly owned Malaysian subsidiaries. Chemrex distributes chemical raw materials, primarily fiber-reinforced polymers, to manufacturers in Southeast Asia for industrial applications, generating the majority of the company's revenue. MRNA Scientific develops and provides blood-based genomic screening services intended to assess disease risk across multiple conditions including eight types of cancer, inflammatory bowel diseases, osteoarthritis, and cardiovascular risks; this business remained limited-revenue in fiscal 2025. In November 2025, the company obtained exclusive ASEAN rights to the VitaGuard™ minimal residual disease platform for cancer recurrence monitoring. [10-K 2026-04-14]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $99.0K | −$830.0K | −$570.2K | $1.23M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | $7.42M | −$2.98M | −$1.84M | $2.38M | [10-K 2026-04-14] |
| FY ended Dec 2024 | $9.51M | −$1.60M | −$2.09M | $2.89M | [10-K 2026-04-14] |
- Quarterly cash burn
- −$285.1K
- Cash runway Estimate
- ~13 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-15 | 17,967,663 | [10-Q 2024-11-15] |
| 2024-12-31 | 17,967,663 | [10-K/A 2025-04-29] |
| 2025-05-15 | 1,796,597 | [10-Q 2025-05-15] |
| 2025-08-18 | 1,796,597 | [10-Q 2025-08-18] |
| 2025-11-14 | 1,796,507 | [10-Q 2025-11-14] |
| 2025-12-31 | 2,417,314 | [10-K 2026-04-14] |
| 2026-05-15 | 2,417,314 | [10-Q 2026-05-15] |
| 2026-08-14 | 2,933,442 | [10-Q 2026-08-14] |
- Shelf registration
- S-3 filed 2025-11-07; no effectiveness notice found in EDGAR [S-3 2025-11-07]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-04-30. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-04-30 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-30] |
| 2025-01-02 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-02] |
| 2024-11-08 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-11-08] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-13 | Tan Lee Su-Leng | grant | 338,709 | — | [4 2026-08-14] |
| 2026-08-13 | Yap Chee Keong | grant | 32,258 | — | [4 2026-08-14] |
| 2026-08-13 | Bin Abdul Hamid Muhammad Azrul | grant | 32,258 | — | [4 2026-08-14] |
| 2026-08-13 | Chong Set Fui | grant | 96,774 | — | [4 2026-08-14] |
| 2026-08-13 | Low Jook Yuen | grant | 16,129 | — | [4 2026-08-14] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-10-07 | 8-K | Material agreement entered; Unregistered sale of equity; Regulation FD disclosure |
| 2026-08-14 | 13D | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 10-Q | Quarterly report |
| 2026-07-28 | 8-K | Other events |
| 2026-06-05 | 8-K | Other events |
| 2026-05-15 | 10-Q | Quarterly report |
| 2026-04-14 | 10-K | Annual report |
| 2026-03-31 | NT 10-K | Notice of late annual report |
| 2026-03-17 | 8-K | Regulation FD disclosure; Other events |
| 2026-02-23 | 8-K | Other events |
| 2026-02-03 | 8-K | Other events |
| 2025-12-30 | 8-K | Shareholder vote results |
Alerts for $BGLC
Email me when BioNexus Gene Lab Corp files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.